Rapid Multiplexing with Opal® Research Kits Now Available on LabSat™ Platform
Lunaphore Technologies S.A., a Swiss medtech firm developing innovative next-generation equipment for cancer research and tissue diagnostics, announces a new rapid multiplexing application for its LabSat™ Research instrument.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190523005082/en/
FFPE IF of tonsil, 6-plex + DAPI. Total staining time: 4h12 (with Opal® 7-Color Manual IHC Kit) (Photo: Business Wire)
Following the signature of a co-marketing agreement between Lunaphore Technologies S.A. and Akoya Biosciences, Inc.; Lunaphore will start providing multiplexing protocols using Akoya’s Opal® immunoassay kits for its staining platform LabSat™ Research, Lunaphore’s first solution to reach the market.
LabSat™ is shown to perform rapid tests on tissue samples under 2.5 hours for a 3-plex plus counterstaining with the Opal® 4-Color Manual IHC Kit; and under 4.5 hours for a 6-plex plus counterstaining with the Opal® 7-Color Manual IHC Kit1. These timeframes present a 3 to 4-fold time improvement compared to the current turnaround times for Opal® 7-Color kit using manual protocols or other automation standards. During the study conducted by both companies, comparable intensity to other staining methods was observed, while reproducibility presented less than 20% of variability1. Moreover, uniformity throughout the tissue section was tested with excellent results, obtaining a signal gradient under 10% over 1 cm of tissue1. This opens opportunities for users to analyze images and quantify signals using Akoya’s imaging and software tools.
These short turnaround times are achieved thanks to a novel microfluidic tissue processor lying at the core of Lunaphore’s innovation, which allows researchers to perform rapid cycles of optimization in order to reach and repeat the desired multiplexed stainings, without the need to invest in traditional workflow automation instruments.
Lunaphore’s co-founder and CTO, Diego G. Dupouy, said: ”The great stainings obtained with our platform are the result of team effort by Lunaphore and Akoya, as we push both of our technologies to the next level. Our goal is to combine short turnaround times with high-quality stainings in order to enable researchers to develop their own immunophenotyping panels in unprecedented times.”
With the arrival of ultra-rapid automated multiplexing in LabSat™, Lunaphore brings together state-of-the-art multiplexing techniques, the high reproducibility of automation systems and an unmatched speed performance, now at the reach of medium and small laboratories.
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company developing next generation tissue autostainers. The award-winning technology based on microfluidics is called FFeX (Fast Fluidic Exchange). It aims to perform assays much faster than standard techniques and has demonstrated good results in tests with cancer patient samples. Lunaphore was founded in 2014 with the vision of bringing –omics like approaches to tissue diagnostics and has been recognized as one of the most innovative companies nationally and internationally.
About LabSat™ Research
LabSat™ Research is a single-slide, ultra-rapid reagent delivery system performing IHC/IF tests on tissue samples for Research Use Only. The breakthrough speed performance of the device is achieved thanks to a novel microfluidic tissue processor lying at the core of Lunaphore’s innovation. This patented technology enables high precision tissue staining, with a drastic reduction of reagent incubation times.
About IHC/IF and multiplexing
Immunohistochemistry (IHC) staining is a technique that involves the use of antibodies to detect the presence of specific cancer biomarkers on a tissue sample. During an IHC test, the tissue is stained with labelled antibodies, producing a coloring on the tissue that is observable with a bright-field microscope. This coloring or staining will signal the presence and localization of specific cancer biomarkers within the tissue. Immunofluorescence (IF) is a similar technique which instead produces fluorescent stainings observable with a fluorescence microscope. IHC and IF are among the most common tests in immuno-oncology research to support scientists in the identification of specific cancer types.
In order to analyze the tumor microenvironment, understanding the spatial organization and co-expression of multiple biomarkers in a tissue section is of key importance. With this purpose, it is possible to stain and visualize several targets simultaneously with a technique known as multiplexed IHC or IF. With Akoya’s Opal® fluorescent kits -4-color and 7-color- 3 and 6 biomarkers, respectively, can be stained at once in order to maximize the obtention of information from each tissue section.
Disclaimer: LabSat™ Research is approved for Research Use Only and not available for diagnostic procedures. Only marketed in Europe.
1 Data on file.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190523005082/en/
Contact information
Irene Tamayo
Lunaphore Corporate Communications
Email: communications@lunaphore.com
Phone:
+41 21 353 58 22
Andrea Büchler
Lunaphore Finance and Business Development
Email:
andrea.buechler@lunaphore.com
Phone
+41 79 598 40 73
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zayed Sustainability Prize Honours Global Pioneers Advancing Progress14.1.2026 03:35:00 EET | Press release
The Zayed Sustainability Prize, the UAE’s pioneering award for innovative solutions to global challenges, today announced the cohort of 2026 winners, celebrating 18 years of empowering communities and driving inclusive, sustainable progress around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113958706/en/ The 2026 winners of the Zayed Sustainability Prize were recognised by the President of the UAE in Abu Dhabi on 13 January 2026 (Photo: AETOSWire) In a ceremony held during Abu Dhabi Sustainability Week (ADSW) and attended by Heads of State, Ministers, and business leaders, His Highness Sheikh Mohamed bin Zayed, President of the UAE, awarded the winners for their outstanding contributions to advancing sustainable development worldwide. H.H. Sheikh Mohamed bin Zayed Al Nahyan said: “The UAE remains firmly committed to supporting efforts that enhance people’s well-being and strengthen the foundations of stabili
Alta Semper Secures USD 57.5 Million from EIB Group and IFC for Growth Fund II to Expand Healthcare Access Across Africa13.1.2026 20:30:00 EET | Press release
Alta Semper Capital LLP (“Alta Semper”), a London-based private equity firm focused on healthcare and consumer investments in high-growth markets, today announced that it has secured USD 57.5 million in commitments to Alta Semper Growth Fund II. These commitments come from a consortium of investors including the European Investment Bank (EIB) Group and the International Finance Corporation (IFC). This landmark partnership was signified earlier today with a momentous signing ceremony held at a Government Ministry in Cairo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113837616/en/ Andrew McDowell (EIB), Cheick Oumar Sylla (IFC), Gelsomina Vigliotti (EIB), Rania Al-Mashat (Minister of Planning, Economic Development and International Cooperation of Egypt), Bassel Rahmy (MSMEDA), Afsane Jetha (CEO, Alta Semper) and Mark Bryson-Richardson MBE (British Ambassador to Egypt) at the signing ceremony in Cairo. (Photo: AETOSWire)
500 Global and Creators HQ Support Creators and Founders Building Startups Collectively Valued at US$130M+13.1.2026 18:00:00 EET | Press release
500 Global, one of the world’s most active Silicon Valley-based venture capital firms1, and Creators HQ, the first content creator hub in the UAE and the Middle East enabling the creator ecosystem globally, announced the Creators Ventures Accelerator program is building and supporting creator-led startups collectively valued at over US$130 million.2 The Creators Ventures Accelerator received over 1,100 applications from content creators and technology startup founders across more than 70 countries. Following a competitive selection process, 21 creators and founders were chosen for the program. This cohort serves a community of 20M+ followers, subscribers, and users across platforms. “Creators represent a growing class of bona fide entrepreneurs, with 50 million creators globally, projected to grow at 10-20% annually over the next 5 years. The first iteration of this industry was built on visibility and virality to monetize. With consumers getting savvier and more discerning, we believe
Nexo Becomes First-Ever Title Partner of the U.S. ATP 500 Dallas Open in Multi-Year Deal13.1.2026 17:30:00 EET | Press release
Nexo, the digital assets wealth platform, has been named the U.S. ATP 500 Dallas Open’s first-ever Title Partner under a multi-year agreement beginning in 2026, as the company advances its long-term brand strategy through leading global sports properties. The partnership was unveiled in Dallas alongside the debut of the Nexo Dallas Open brand and the resurfacing of two public tennis courts in North Texas. As one of only two ATP 500 tournaments in the U.S. and the country’s sole indoor ATP Tour championship, the Dallas Open places Nexo among a limited group of ATP 500 title partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113901822/en/ The Nexo Dallas Open “This partnership with Nexo represents a transformative milestone for the Dallas Open,” said Tournament Director Peter Lebedevs. “Securing a title sponsor of this caliber as we launch into year two as an ATP 500 event continues to elevate our tournament on the gl
Blue Matter Establishes New Capabilities in Biopharma Research & Development Led by Partner, Tara Austraat-Churik13.1.2026 16:01:00 EET | Press release
Blue Matter is pleased to announce that it has established a practice area dedicated to serving clients in biopharmaceutical Research & Development (R&D). The practice is led by Tara Austraat-Churik, a Partner who joined the firm in September 2025. Tara Austraat-Churik has been serving life science clients for more than 20 years. Her areas of expertise include strategy development and implementation, operating model and organizational design, and process optimization in R&D and Medical Affairs. Prior to joining Blue Matter, she served as Managing Director in R&D, Health, Science, and Wellness at EY. She has a robust background in consulting, which also includes roles at Booz Allen Hamilton, Navitas, WPP, and IBM. She holds a BA and MA from the University of Notre Dame and an MSc in Translational Medicine from the University of Edinburgh. The R&D practice, according to Austraat-Churik, exists to help biopharma companies simplify and accelerate the pathway to market. She adds, “R&D organ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom